Method for EGFR directed combination treatment of cancer

• 收藏
• 分享

专利权人:

Boehringer Ingelheim International GmbH

发明人:

Denis, Louis,Lorence, Robert,Shahidi, Mehdi,Solca, Flavio

申请号：

AU2012257727

公开号：

AU2012257727A1

申请日:

2012.05.16

申请国别(地区):

AU

年份:

2013

代理人:

摘要：

The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weeklyiv dose of 50 to 500 mg/m

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/